ASCO: Direct Oral Anticoagulant Therapy Feasible for Cancer Patients
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, June 6, 2023 -- Direct oral anticoagulant (DOAC) treatment is noninferior to low-molecular-weight heparin (LMWH) for preventing recurrent venous thromboembolism (VTE) in cancer patients, according to a study published online June 2 in the Journal of the American Medical Association to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago.
Deborah Schrag, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues assessed the effectiveness of DOACs (335 patients) versus LMWH (336 patients) for preventing recurrent VTE in patients with cancer (any invasive solid tumor, lymphoma, multiple myeloma, or chronic lymphocytic leukemia) over six months.
The researchers found that rates of recurrent VTE were 6.1 percent in the DOAC group versus 8.8 percent in the LMWH group (difference, −2.7 percent), consistent with the prespecified noninferiority criterion. None of the six prespecified secondary outcomes were significantly different between the groups. Major bleeding did not meet the noninferiority criterion, as it occurred in 5.2 percent of the DOAC group versus 5.6 percent of the LMWH group (difference, −0.4 percent; 1-sided 95 percent confidence interval, –100 percent to 2.5 percent). Severe adverse events occurred in 33.8 percent and 35.1 percent of the groups, respectively. Anemia and death were the most common serious adverse events reported.
"These findings support use of a DOAC to prevent recurrent VTE in patients with cancer," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Rate of Venous Thromboembolism Increased With Cancer Surgery
FRIDAY, Feb. 2, 2024 -- The rate of venous thromboembolism is increased in association with cancer surgery, according to a study published online Feb. 2 in JAMA Network...
Clot Risk High With Oral Contraceptives for Those at Genetic Risk
FRIDAY, Dec. 1, 2023 -- Oral contraceptive (OC) use is associated with an increased risk for developing a venous thromboembolism (VTE), particularly among women with a high...
Link Explored for NSAID Use, Hormonal Contraception, VTE Risk
MONDAY, Sept. 11, 2023 -- In women of reproductive age, nonsteroidal anti-inflammatory drug (NSAID) use is associated with venous thromboembolism, with significantly more...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.